How Long Can You Live With Mitral Annular Calcification?

Most people with mitral annular calcification (MAC) live for years or even decades without serious complications, because the condition often stays mild and produces no symptoms. When it does shorten life, it does so indirectly: a large meta-analysis found that people with MAC face roughly 75 percent higher all-cause mortality and 85 percent higher cardiovascular mortality compared with those without it. But those are averages across all severities and ages. The real answer depends on how much calcium has built up, whether the mitral valve still works properly, what other conditions are present, and whether the calcification keeps progressing.

What MAC Actually Does

MAC is a buildup of calcium deposits along the fibrous ring that supports the mitral valve, the gate between the left atrium and the left ventricle. In most cases it sits there quietly. The calcium does not usually interfere with how the valve opens and closes, so a person can carry mild MAC for years without knowing it exists. It typically shows up as an incidental finding on an echocardiogram ordered for something else.

Problems start when the deposits grow large enough to stiffen or distort the valve leaflets. This can cause the valve to narrow (mitral stenosis), to leak (mitral regurgitation), or both. When either problem becomes severe, pressure backs up into the left atrium and eventually the lungs, triggering heart failure symptoms like breathlessness, fatigue, and fluid retention.¹

The Survival Numbers

Several large studies have tracked what happens to people after MAC is detected. In the Framingham Heart Study, MAC independently raised the risk of cardiovascular death by about 60 percent and all-cause death by about 30 percent, even after accounting for traditional risk factors like high blood pressure and cholesterol. For each additional millimeter of calcification, the risk of cardiovascular death climbed by roughly 10 percent.² A separate meta-analysis pooling results from multiple studies reported a hazard ratio of about 1.76 for all-cause death and 1.85 for cardiovascular death in people with MAC.³

Those numbers sound alarming, but context matters. MAC is overwhelmingly a disease of older adults, and the people who have it tend to already carry a heavy load of cardiovascular risk factors. The hazard ratios tell you that MAC adds risk on top of those factors, not that it alone is a death sentence. Many people with mild MAC go on to die of something entirely unrelated.

Where outcomes get grimmer is at the severe end. A Mayo Clinic study of over 24,000 patients found that those with MAC and mitral valve dysfunction had about 76 percent survival at one year, compared with 86 percent for people who had valve dysfunction without MAC. Among patients with symptomatic valve problems who did not receive any valve intervention, four-year survival dropped to roughly 35 percent. And patients who developed severe calcific mitral stenosis faced close to 80 percent mortality over eight years if they went untreated.¹

Two-year mortality also varies by pattern: about 14 percent for MAC without valve dysfunction, 26 percent for MAC with at least moderate regurgitation, and 21 percent for MAC with at least moderate stenosis.⁴

How Fast MAC Progresses

Not everyone with mild MAC ends up with a severely calcified valve. A study following over 11,000 patients with MAC found that about a third of those starting with mild or moderate calcification had progressed to severe MAC by ten years. Women progressed faster than men, and those who already had moderate disease at baseline were six times more likely to reach severe than those who started mild.⁵

Actual valve dysfunction, meaning stenosis or regurgitation severe enough to matter clinically, developed in about 10 percent of all MAC patients by ten years. But that rate differed sharply by starting severity: only 4 percent of mild cases, versus 23 percent of moderate and 60 percent of severe cases. Female sex was an independent predictor of developing valve disease, roughly doubling the risk even after adjusting for how severe the calcification already was.⁵

In a separate cohort with mild MAC followed for a median of nearly five years, about 215 patients went on to develop valve dysfunction. Among those, mitral regurgitation was far more common (79 percent of cases) than mitral stenosis (17 percent), with a small group developing both.⁶

Among the factors that predicted faster progression, higher systolic blood pressure and wider pulse pressure stood out. A study of 138 patients found that about 31 percent showed progressive MAC on follow-up imaging, and those who progressed had higher blood pressures at baseline.⁷ This gives at least some handle on slowing the process, since blood pressure is treatable.

Why Kidney Disease Makes Everything Worse

MAC is far more common and more dangerous in people with chronic kidney disease (CKD). Failing kidneys lose the ability to regulate calcium and phosphate properly. Phosphate levels creep up, and the calcium-phosphate product rises, creating conditions that actively drive calcium into soft tissues, including heart valves.⁸

A study of CKD patients confirmed that those with MAC had significantly higher plasma calcium and phosphate levels than those without it. The proportion of patients on dialysis and those taking calcium-containing phosphate binders was also higher in the MAC group.⁹ In the large CRIC (Chronic Renal Insufficiency Cohort) study, both lower kidney function and elevated phosphate independently predicted MAC.¹⁰

Fibroblast growth factor 23 (FGF-23), a hormone the body produces to manage phosphate, has also been linked to faster MAC progression. In the Multi-Ethnic Study of Atherosclerosis, higher FGF-23 was associated with accelerated annual increases in MAC calcium scores, even after adjusting for demographics and other cardiovascular risk factors.¹¹ This suggests that the mineral metabolism pathway is not just a bystander but actively fuels the problem.

Stroke Risk and Other Cardiovascular Fallout

MAC does not just threaten the valve it sits on. It acts as a marker, and in some cases a direct contributor, to a broader set of cardiovascular problems. The link with stroke is particularly well documented. In the Multi-Ethnic Study of Atherosclerosis, MAC roughly doubled the risk of ischemic stroke, and this held even after adjusting for atrial fibrillation and left atrial size, two factors that might otherwise explain the connection.¹² The Strong Heart Study found an even stronger association: after adjusting for clinical and inflammatory markers, MAC was linked to about 2.4 times the risk of stroke.¹³

The mechanism behind this is likely a combination of factors. MAC can promote turbulent blood flow near the valve, encouraging clot formation. It also tracks closely with systemic atherosclerosis; studies have found that the presence of MAC and aortic valve calcification together can help predict significant coronary artery disease.¹⁴ The calcification you can see on the mitral ring is often the visible tip of a wider process happening throughout the cardiovascular system.

MAC has also been linked to congestive heart failure and coronary events like heart attacks. The Framingham data showed that MAC raised the risk of new cardiovascular disease by about 50 percent overall.² And in patients who have already undergone transcatheter aortic valve replacement for a different valve problem, having MAC nearly doubles the risk of dying afterward.¹

Heart Rhythm and Conduction Problems

Because the mitral annulus sits close to the heart’s electrical wiring, heavy calcification can interfere with signal conduction. One classic study reported 16 cases of high-grade atrioventricular block among MAC patients, with 21 eventually needing pacemakers for slow heart rhythms.¹⁵ A more recent case report described a relatively young patient who developed complete heart block because the calcification had infiltrated the basal septum and the bundle of His, the critical electrical highway connecting the upper and lower chambers.¹⁶

This is not the most common complication, but it is worth knowing about because the symptoms, such as fainting, dizziness, or extreme fatigue, can appear suddenly and be misattributed to age or deconditioning. If you have known MAC and develop unexplained lightheadedness or near-fainting, mention the MAC to your doctor.

Treatment Options and Their Limits

For most mild MAC, there is no specific treatment beyond managing the cardiovascular risk factors that drive it: blood pressure control, cholesterol management, kidney health, and avoiding excessive calcium and phosphate imbalances. No medication has been shown to reverse calcification once it has formed.

When MAC progresses to severe valve dysfunction causing symptoms, intervention becomes necessary, but it is among the trickiest situations in cardiac surgery. Conventional mitral valve replacement in patients with MAC carries higher operative mortality (about 5.8 percent compared with 4.4 percent in patients without MAC) and an increased risk of complications like kidney injury and the need for repeat intubation.¹⁷ The calcified ring is hard, brittle, and sits next to vital structures, making it prone to catastrophic complications during surgery, including disruption of the groove between the atrium and ventricle.¹⁸

Transcatheter approaches, which avoid open-heart surgery by threading a new valve through a catheter, have been developed specifically for high-risk MAC patients. Early results were sobering: in one registry of 106 extreme-risk patients, 30-day mortality was 25 percent and one-year mortality reached about 54 percent. On the other hand, those who survived the first month had roughly 64 percent survival at one year, and most of them felt substantially better.¹⁹

More recent data from the SUMMIT-MAC study, using a purpose-built device called Tendyne, showed meaningful improvement. In 103 patients with a mean age of 78 and severe MAC, technical success was achieved in about 94 percent of cases. Thirty-day mortality dropped to around 7 percent, and about 60 percent of patients were free from death or heart failure hospitalization at 12 months.²⁰ That is a major step forward from the earlier registry data, though it still reflects a high-risk population.

The Unexpected Link With Osteoporosis

One of the more surprising findings in MAC research is its connection with bone loss. The underlying idea is that calcium leaving the skeleton does not simply vanish; it can end up depositing in soft tissues, including heart valves. In one study, over half of women with MAC also had osteoporosis, compared with about 18 percent of women without MAC. Bone mineral density scores and age were the strongest independent predictors of MAC, outranking traditional cardiovascular risk factors.²¹

This association has been confirmed in Japanese women as well: elderly women with MAC had significantly lower bone mineral content than controls, supporting the idea that severe bone loss contributes to ectopic calcium deposition.²² More recently, the Multi-Ethnic Study of Atherosclerosis showed that lower bone mineral density predicted faster progression of both aortic valve and mitral annular calcification over time, in both women and men.²³

This raises the question of whether treating osteoporosis could slow MAC progression. No trial has directly tested this, but the biological plausibility is enough that researchers have flagged it as worth investigating. For now, the practical takeaway is that postmenopausal women with osteoporosis should be aware they are at higher risk for MAC and might benefit from echocardiographic screening if they develop cardiac symptoms.

Endocarditis and Infection Risk

A less common but serious complication is infective endocarditis, an infection of the heart valve surfaces. The turbulent blood flow created by calcified tissue erodes the endothelium and exposes the rough, calcium-laden surface beneath, giving bacteria a foothold during episodes of transient bacteremia, the kind that can happen during dental procedures or minor infections.²⁴ Older case series have documented endocarditis as an occasional complication, along with arterial emboli likely originating from the calcified surface.¹⁵

This does not mean every person with MAC needs antibiotic prophylaxis before dental work. Current guidelines reserve that recommendation for higher-risk conditions like prosthetic valves or prior endocarditis. But if MAC is severe or associated with significant regurgitation, it is worth discussing with a cardiologist whether extra precautions make sense.

How MAC Gets Graded

If you have been told you have MAC, the severity grading matters more than the diagnosis itself. Echocardiography is the first-line tool and can classify the calcification as mild, moderate, or severe based on how much of the annulus is involved and whether the valve leaflets are affected. For patients being considered for surgery or transcatheter intervention, CT scanning adds important detail. A CT-based scoring system grades MAC on a scale of 2 to 12, incorporating the calcium score, the angle of involvement around the annulus, whether calcification extends into the left ventricular outflow tract, and whether it infiltrates the heart muscle itself.²⁵ Higher scores predict greater surgical complexity and higher procedural risk.

For patients living with MAC who are not candidates for intervention, the most important piece of imaging data is whether the valve is still functioning normally. A follow-up echocardiogram every one to three years, depending on severity, can catch the transition from harmless calcification to clinically meaningful valve disease before symptoms become severe. The window between early valve dysfunction and advanced disease is where intervention, if it is going to happen, has the best chance of improving outcomes.

1
PubMed Central. Mitral Annular Calcification: Understanding the Disease and Treatment Options
2
PubMed. Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study
3
PubMed. Relationships between mitral annular calcification and cardiovascular events: A meta-analysis
4
PubMed. Mitral Annular Calcification: Natural History, Prognosis, and Clinical Outcomes
5
PubMed. Natural History of Mitral Annular Calcification and Calcific Mitral Valve Disease
6
PubMed. Progression of Mild Mitral Annulus Calcification to Mitral Valve Dysfunction and Impact on Mortality
7
PubMed Central. Risk Factors and Outcomes With Progressive Mitral Annular Calcification
8
Clinical Kidney Journal. Valvular calcification in chronic kidney disease: new insights from recent clinical and preclinical studies
9
PubMed. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease
10
PubMed Central. Prevalence and correlates of mitral annular calcification in adults with chronic kidney disease: Results from CRIC study
11
PubMed Central. Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis
12
PubMed. Mitral annular calcification as a predictor of stroke in the multiethnic study of atherosclerosis
13
PubMed. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study
14
PubMed. Mitral annular calcification and aortic valve calcification may help in predicting significant coronary artery disease
15
The American Journal of Medicine. Calcification of the mitral annulus: Etiology, clinical associations, complications and therapy
16
HeartRhythm Case Reports. Caseous calcification of the mitral annulus presenting with symptomatic complete heart block
17
PubMed. Characterizing Risks Associated With Mitral Annular Calcification in Mitral Valve Replacement
18
JTCVS Techniques. Mitral valve replacement in severe mitral annular calcification: Avoiding disaster
19
PubMed. 1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification
20
PubMed. Transcatheter Mitral Valve Replacement for Severe Mitral Annular Calcification: Primary Outcomes From the SUMMIT-MAC Study
21
PubMed. Mitral annular calcification is associated with osteoporosis in women
22
PubMed. The influence of severe bone loss on mitral annular calcification in postmenopausal osteoporosis of elderly Japanese women
23
PubMed Central. Bone mineral density and long-term progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis
24
PubMed Central. Infective endocarditis on mitral annular calcification: a case report
25
European Heart Journal – Imaging Methods and Practice. Mitral annular calcification score by computed tomography in patients undergoing mitral valve surgery